AZN Shares Rise After COPD Medication Succeeds in Two Advanced Trials

AstraZeneca's Tozorakimab Shows Promise in COPD Trials

AstraZeneca (AZN) saw its stock climb nearly 3% on Friday following the announcement that its investigational monoclonal antibody, tozorakimab, achieved the main goal in two phase III clinical trials for chronic obstructive pulmonary disease (COPD).

The OBERON and TITANIA studies compared tozorakimab to a placebo in adults with symptomatic COPD who had experienced at least two moderate or one severe flare-up within the previous year. Both trials met their primary objective, as tozorakimab reduced the yearly rate of moderate-to-severe COPD exacerbations in former smokers compared to placebo. This benefit was also observed in the broader group, which included both current and former smokers, regardless of blood eosinophil levels or lung function severity.

While AstraZeneca did not share specific data, the company plans to present comprehensive results from these studies at an upcoming medical conference.

Stock Market Reaction and Industry Context

AstraZeneca's shares edged higher on Friday, reflecting optimism about tozorakimab’s potential in treating COPD—a disease that remains the third leading cause of death worldwide. With approximately 400 million people affected globally and limited treatment choices, new therapies are highly anticipated. Tozorakimab targets IL-33, a key inflammatory pathway. Competing drugs from Sanofi/Regeneron (itepekimab) and Roche (astegolimab) have previously delivered mixed or negative results in late-stage trials, highlighting the importance of AstraZeneca’s positive findings.

So far this year, AstraZeneca’s stock has outperformed the broader medical and genetics industry, as illustrated below.

Source: Zacks Investment Research

Further Development of Tozorakimab

Beyond OBERON and TITANIA, AstraZeneca is conducting two additional phase III trials—PROSPERO and MIRANDA—for tozorakimab in COPD, with results expected in the first half of 2026. The drug is also being assessed in advanced studies for severe viral lower respiratory tract infections and in a mid-stage trial for asthma.

AstraZeneca PLC Share Price

Current Zacks Rank for AstraZeneca

Free Report: The Next Wave of AI Investment Opportunities

The upcoming surge in artificial intelligence is expected to generate substantial wealth for early investors, potentially adding trillions to the global economy and transforming many industries. Those who invested in companies like Nvidia at the right moment have already seen significant returns.

However, the rapid growth of the initial wave of AI stocks may soon slow, paving the way for a new set of innovative companies to lead the next phase of expansion. Zacks’ report, AI Boom 2.0: The Second Wave, highlights four lesser-known firms that could become major players in the evolving AI landscape.

Additional Free Stock Analysis Reports